Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Executing Clinical Research in Dementia with Lewy Bodies (DLB)

Core Insights - Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing drugs for neurodegenerative disorders, specifically targeting dementia with Lewy bodies (DLB) and Alzheimer's disease [1][4] - The company has launched a new podcast episode during DLB Awareness Month, discussing the clinical research and unique symptoms associated with DLB [1][2] Company Overview - Cognition Therapeutics is engaged in discovering and developing small molecule therapeutics aimed at age-related degenerative disorders of the central nervous system and retina [4] - The lead candidate, CT1812, is currently being investigated in clinical programs for Alzheimer's disease, DLB, and dry age-related macular degeneration [4] SHIMMER Study Details - The SHIMMER study is a Phase 2 clinical trial involving 130 adults with mild-to-moderate DLB, assessing the efficacy of CT1812 [5][6] - Participants are randomized to receive either a placebo or one of two doses of CT1812 (100 mg or 300 mg) for six months, with various cognitive assessments conducted throughout the study [5] - The study is supported by a grant from the National Institute on Aging totaling approximately $30 million and is being conducted at over 30 sites in the U.S. [6]